ZA200809783B - System and method for determining individualized medical intervention for a disease state - Google Patents

System and method for determining individualized medical intervention for a disease state

Info

Publication number
ZA200809783B
ZA200809783B ZA2008/09783A ZA200809783A ZA200809783B ZA 200809783 B ZA200809783 B ZA 200809783B ZA 2008/09783 A ZA2008/09783 A ZA 2008/09783A ZA 200809783 A ZA200809783 A ZA 200809783A ZA 200809783 B ZA200809783 B ZA 200809783B
Authority
ZA
South Africa
Prior art keywords
disease state
medical intervention
individualized medical
determining individualized
determining
Prior art date
Application number
ZA2008/09783A
Other languages
English (en)
Inventor
Robert Penny
Hoff Daniel D Von
Original Assignee
Molecular Profiling Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38724046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809783(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molecular Profiling Inst Inc filed Critical Molecular Profiling Inst Inc
Publication of ZA200809783B publication Critical patent/ZA200809783B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/10—Ontologies; Annotations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioethics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
ZA2008/09783A 2006-05-18 2008-11-17 System and method for determining individualized medical intervention for a disease state ZA200809783B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74764506P 2006-05-18 2006-05-18
PCT/US2007/069286 WO2007137187A2 (en) 2006-05-18 2007-05-18 System and method for determining individualized medical intervention for a disease state

Publications (1)

Publication Number Publication Date
ZA200809783B true ZA200809783B (en) 2010-02-24

Family

ID=38724046

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/09783A ZA200809783B (en) 2006-05-18 2008-11-17 System and method for determining individualized medical intervention for a disease state

Country Status (14)

Country Link
US (7) US8700335B2 (enExample)
EP (2) EP3399450A1 (enExample)
JP (7) JP2009537154A (enExample)
KR (1) KR101356305B1 (enExample)
CN (2) CN103424541B (enExample)
AU (1) AU2007253740A1 (enExample)
BR (1) BRPI0711011A2 (enExample)
CA (1) CA2651995C (enExample)
CO (1) CO6141496A2 (enExample)
IL (8) IL301804A (enExample)
MX (1) MX2008014608A (enExample)
RU (1) RU2008146868A (enExample)
WO (1) WO2007137187A2 (enExample)
ZA (1) ZA200809783B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP3399450A1 (en) 2006-05-18 2018-11-07 Caris MPI, Inc. System and method for determining individualized medical intervention for a disease state
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20080280777A1 (en) * 2007-05-11 2008-11-13 Translational Genomics Research Institute Method for determining the effects of external stimuli on biological pathways in living cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2245460B1 (en) * 2008-01-25 2013-12-25 Berg LLC Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
CN107092770A (zh) 2008-05-12 2017-08-25 皇家飞利浦电子股份有限公司 医学分析系统
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
SMT201700084T1 (it) 2008-08-04 2017-03-08 Wyeth Llc Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20100069298A1 (en) * 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
EP2347009A4 (en) * 2008-10-14 2012-05-30 Caris Mpi Inc GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE
FR2937801B1 (fr) * 2008-10-23 2010-12-03 Souriau Ensemble de connexion a verrouillage rapide et procede d'accouplement et de desaccouplement de l'ensemble
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
PT3301446T (pt) * 2009-02-11 2020-07-14 Caris Mpi Inc Perfilagem molecular de tumores
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
WO2010118782A1 (en) * 2009-04-17 2010-10-21 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
CN106228017A (zh) * 2009-09-30 2016-12-14 帕斯维基因组学公司 基于基因组的药物管理系统
JP6126382B2 (ja) * 2010-01-13 2017-05-10 ワイス・エルエルシー 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
FI20105252A0 (fi) 2010-03-12 2010-03-12 Medisapiens Oy Menetelmä, järjestely ja tietokoneohjelmatuote biologisen tai lääketieteellisen näytteen analysoimiseen
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
CN101984070B (zh) * 2010-09-21 2013-04-24 广州益善生物技术有限公司 一种c-KIT基因突变检测液相芯片
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
JP6367557B2 (ja) * 2011-01-07 2018-08-01 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 臨床データ解析モジュールへの統合的なアクセスおよび臨床データ解析モジュールとの相互作用
US20130339060A1 (en) * 2011-02-17 2013-12-19 University Hospitals Of Cleveland Method and system for extraction and analysis of inpatient and outpatient encounters from one or more healthcare related information systems
EP2681709A4 (en) * 2011-03-04 2015-05-06 Kew Group Llc PERSONALIZED MEDICAL MANAGEMENT SYSTEM, NETWORKS AND ASSOCIATED METHODS
WO2014019181A1 (zh) * 2012-08-01 2014-02-06 华为技术有限公司 一种控制信道传输方法及装置
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN110872617A (zh) 2012-09-04 2020-03-10 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103784465B (zh) * 2012-11-02 2015-11-11 上海交通大学医学院附属瑞金医院 乙醛脱氢酶2作为蒽环类化疗药物处理肿瘤细胞时药物靶标的应用
KR101449418B1 (ko) * 2012-12-27 2014-10-14 한국식품연구원 비만에 대한 영양 유전체 정보를 제공하는 방법 및 이를 이용한 장치
CN105144179B (zh) * 2013-01-29 2019-05-17 分子健康股份有限公司 用于临床决策支持的系统和方法
CN104630055A (zh) * 2013-11-08 2015-05-20 西安科技大学 原位杂交系统的主控板
ES2784450T3 (es) 2013-12-28 2020-09-25 Guardant Health Inc Métodos y sistemas para detectar variantes genéticas
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN105512508B (zh) * 2014-09-22 2018-05-15 深圳华大基因研究院 自动生成基因检测报告的方法及装置
US9983026B2 (en) * 2014-09-25 2018-05-29 Texas Instruments Incorporated Multi-level rotational resolvers using inductive sensors
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-conjugated immune reagents
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
JP2018532992A (ja) * 2015-09-09 2018-11-08 ソマロジック, インコーポレイテッドSomaLogic, Inc. 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
EP3390668A4 (en) 2015-12-17 2020-04-01 Guardant Health, Inc. METHODS OF DETERMINING THE NUMBER OF TUMOR GENE COPIES BY ACELLULAR DNA ANALYSIS
KR102393306B1 (ko) * 2016-01-18 2022-04-29 줄리안 고프 유전자형으로부터 표현형을 결정하는 방법
WO2017139592A1 (en) 2016-02-12 2017-08-17 Genosecurity, LLC Security enhanced portable data store and processor for allowing secure and selective access to genomic data
JP2019516393A (ja) 2016-03-18 2019-06-20 カリス サイエンス インコーポレイテッド オリゴヌクレオチドプローブおよびその使用
IL306052A (en) 2016-05-25 2023-11-01 Caris Science Inc Oligonucleotide probes and their uses
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
ES2840003T3 (es) 2016-09-30 2021-07-06 Guardant Health Inc Métodos para análisis multi-resolución de ácidos nucleicos libres de células
CN106650256B (zh) * 2016-12-20 2020-01-03 安徽安龙基因科技有限公司 一种分子诊疗精准医学平台
JP2021501333A (ja) * 2017-10-27 2021-01-14 フロンティア ダイアグノスティクス リミテッド ライアビリティ カンパニー がん腫評価のための質量分析方法
US11227692B2 (en) * 2017-12-28 2022-01-18 International Business Machines Corporation Neuron model simulation
CN119753091A (zh) 2018-04-02 2025-04-04 格里尔公司 用于扩增与癌症相关联的cfDNA分子的化验板
JP6920251B2 (ja) 2018-06-29 2021-08-18 シスメックス株式会社 解析方法、情報処理装置、プログラム
WO2020069350A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
US10978196B2 (en) 2018-10-17 2021-04-13 Tempus Labs, Inc. Data-based mental disorder research and treatment systems and methods
CN109584958A (zh) * 2018-11-29 2019-04-05 江苏医联生物科技有限公司 一种基于云计算基因序列数据质控管理方法
EP4369356A3 (en) 2018-11-30 2024-07-24 Caris MPI, Inc. Next-generation molecular profiling
KR102217060B1 (ko) * 2019-01-30 2021-02-18 (주)메디젠휴먼케어 개인별 단일염기 다형성 분석 및 관리 장치
CN113661249B (zh) 2019-01-31 2025-07-01 夸登特健康公司 用于分离无细胞dna的组合物和方法
AU2020326626A1 (en) 2019-08-02 2022-03-10 Tempus Ai, Inc. Data-based mental disorder research and treatment systems and methods
JP2021069284A (ja) * 2019-10-29 2021-05-06 国立研究開発法人国立循環器病研究センター 脳梗塞治療支援システム
AU2020397802A1 (en) 2019-12-02 2022-06-16 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11872049B2 (en) * 2020-06-10 2024-01-16 Shane Harrah System and method for detecting presence of illness symptoms
WO2022060976A1 (en) * 2020-09-17 2022-03-24 The Broad Institute, Inc. Methods for treating infections
WO2024086238A1 (en) * 2022-10-19 2024-04-25 Net/Bio, Inc. Methods and systems for assessing dose-dependent response of a subject to an intervention

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725550A (en) 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
IL82930A (en) 1984-07-19 1988-04-29 Channa Shalitin Antibodies for the detection of mammalian carcinomas and their preparation
US4957859A (en) 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
US6013431A (en) 1990-02-16 2000-01-11 Molecular Tool, Inc. Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators
US6221620B1 (en) 1991-04-24 2001-04-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies specific for human thymidylate synthase
EP0655090B1 (en) 1992-04-27 2000-12-27 The Trustees Of Dartmouth College Detection of gene sequences in biological fluids
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
DE69524182T3 (de) 1994-08-12 2009-07-09 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nukleinsäuresonden umfassend ein Fragment des 17Q-verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
PT705903E (pt) 1994-08-12 2001-11-30 Myriad Genetics Inc Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
GB9422814D0 (en) 1994-11-11 1995-01-04 Medinnova Sf Chemical method
US6143737A (en) 1995-06-23 2000-11-07 Georgetown University Progesterone analogs to reverse multidrug resistance
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US5998151A (en) 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
WO1997022689A1 (en) 1995-12-18 1997-06-26 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998033518A1 (en) 1997-02-04 1998-08-06 Sloan-Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6150514A (en) 1997-04-09 2000-11-21 University Of Utah Research Foundation 14 Kilobase deletion in the promoter region of BRCA1 in a breast cancer family
GB9715034D0 (en) 1997-07-18 1997-09-24 Zeneca Ltd Assay
JP2002505431A (ja) * 1998-02-25 2002-02-19 アメリカ合衆国 迅速な分子プロファイリングのための細胞アッセイ法
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
EP1131470A4 (en) * 1998-10-28 2004-11-10 Vysis Inc CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS
EP1151300B1 (en) 1998-12-23 2010-04-28 Medsaic Pty Limited An assay to detect a binding partner
US6613510B2 (en) 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
DE19922052A1 (de) 1999-05-14 2000-11-16 Theragen Molekularmedizinische Verfahren zum Nachweis der Wirkung von unterschiedlichen Chemotherapeutika und/oder einer Strahlentherapie bei malignen Erkrankungen sowie Verfahren zur Auswahl wirkungsvoller therapeutischer Mittel zu deren Therapie
KR100543857B1 (ko) 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US7135303B2 (en) 2000-02-28 2006-11-14 The United States Of America As Represented By The Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
JP2004505612A (ja) 2000-03-31 2004-02-26 ユニバーシティ・オブ・サザン・カリフォルニア 食道腺ガンに関する後成的配列
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
EP1158055A1 (fr) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Méthode pour le diagnostic de cancers
WO2001092338A1 (en) 2000-06-01 2001-12-06 The Brigham And Women's Hospital, Inc. Diagnosis of endometrial precancers
AU2001277172A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
CA2420176A1 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20030029847A (ko) * 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
CA2420193A1 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE10043591A1 (de) 2000-09-01 2002-03-14 Max Delbrueck Centrum Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
US7711580B1 (en) * 2000-10-31 2010-05-04 Emergingmed.Com System and method for matching patients with clinical trials
WO2002044715A1 (en) 2000-11-28 2002-06-06 Surromed, Inc. Methods for efficiently minig broad data sets for biological markers
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US7049059B2 (en) 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
CA2432976A1 (en) 2000-12-21 2002-08-08 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes
US20020150966A1 (en) * 2001-02-09 2002-10-17 Muraca Patrick J. Specimen-linked database
CA2377213A1 (en) 2001-03-20 2002-09-20 Ortho-Clinical Diagnostics, Inc. Method for providing clinical diagnostic services
EP1411120B1 (en) 2001-07-05 2010-01-13 Taiho Pharmaceutical Company Limited Dna arrays for measuring sensitivity to anticancer agent
US20030013120A1 (en) 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
CN1408883A (zh) * 2001-09-30 2003-04-09 上海博德基因开发有限公司 一种基于基因芯片进行抗肿瘤药物筛选的方法
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1456364B1 (en) 2001-12-21 2011-03-23 The Wellcome Trust Mutations in the b-raf gene
WO2003061564A2 (en) * 2001-12-21 2003-07-31 Gene Logic, Inc. Gene expression profiles in liver disease
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
JP3481231B2 (ja) 2002-03-05 2003-12-22 三洋電機株式会社 有機エレクトロルミネッセンス表示装置およびその製造方法
EP3115470B1 (en) 2002-03-13 2018-07-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2003104474A2 (en) 2002-06-07 2003-12-18 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
AT500648B1 (de) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
US20060008807A1 (en) 2002-08-23 2006-01-12 O'hara Shawn M Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
WO2004024892A2 (en) * 2002-09-12 2004-03-25 Chondrogene Inc. Identification of sequences particularly useful for the diagnosis and identification of therapeutic targets for osteoarthritis
AU2003303144A1 (en) * 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2504605C (en) 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US20050283386A1 (en) * 2002-11-20 2005-12-22 Aventis Pharmaceuticals Inc. Method and system for marketing a treatment regimen
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
WO2004074518A1 (en) 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
NZ587776A (en) 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
US7361460B2 (en) 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
US20050084913A1 (en) 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
US8150627B2 (en) 2003-05-15 2012-04-03 Illumina, Inc. Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns
US20070105105A1 (en) 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US7319007B2 (en) 2003-06-12 2008-01-15 Pomeranian Academy Of Medicine Determining a predisposition to cancer
CA2528529A1 (en) 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
EP1980629A3 (en) 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
WO2005031002A2 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
CA2540894A1 (en) * 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
EP1756137A4 (en) 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
EP1538219A1 (en) 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for type 1 diabetes mellitus
CA2549518A1 (en) 2003-12-12 2005-07-14 University Of Rochester Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
EP1711632A4 (en) 2004-01-19 2009-03-11 Technion Res & Dev Foundation DIAGNOSTIC TEST FOR PARKINSON
US20050181377A1 (en) * 2004-02-13 2005-08-18 Markovic Svetomir N. Targeted cancer therapy
WO2005092038A2 (en) 2004-03-22 2005-10-06 The Johns Hopkins University Methods for the detection of nucleic acid differences
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CN107988363A (zh) 2004-03-31 2018-05-04 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
DK2163650T3 (en) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
US8135595B2 (en) 2004-05-14 2012-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Computer systems and methods for providing health care
EP1784501B1 (en) 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
EP1751309B1 (en) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
JP2008501336A (ja) 2004-06-02 2008-01-24 ソースフアーム・インコーポレイテツド Ｒｎａを含有する微小胞およびそのための方法
CA2569502A1 (en) 2004-06-04 2005-12-15 Veridex Llc Diagnosing or predicting the course of breast cancer
US20060018897A1 (en) 2004-06-28 2006-01-26 Transtarget Inc. Bispecific antibodies
EP3342877B1 (en) 2004-09-30 2020-01-29 Epigenomics AG Method for providing dna fragments derived from an archived sample
WO2006050475A2 (en) 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with neurological diseases
CA2587765A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US7442507B2 (en) 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
WO2006087233A2 (en) 2005-02-21 2006-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells
WO2006098978A1 (en) 2005-03-09 2006-09-21 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
AU2006234897A1 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
EP1722231A3 (en) 2005-04-27 2009-03-11 MPB MelTec Patent- und Beteiligungsgesellschaft mbH Method for identification of somatic stem cells
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
US20070020657A1 (en) 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007001868A1 (en) 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
US20070134687A1 (en) 2005-09-12 2007-06-14 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
JP2009509171A (ja) 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
CA2624086A1 (en) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
US20090226902A1 (en) 2005-10-12 2009-09-10 Hemmo Arjan Drexhage Method to Diagnose or Screen for Inflammatory Diseases
ES2324435B1 (es) 2005-10-27 2010-05-31 Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas.
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090215642A1 (en) 2005-12-09 2009-08-27 Knudson Alfred G Methods and Compositions for Assessing Alterations in Gene Expression Patterns in Clinically Normal Tissues Obtained from Heterozygous Carriers of Mutant Genes Associated with Cancer and Methods of Use Thereof
JP2007175021A (ja) 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
US7593913B2 (en) 2006-01-11 2009-09-22 Siemens Medical Solutions Usa, Inc. Systems and method for integrative medical decision support
NZ593224A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
CN101410715A (zh) 2006-01-27 2009-04-15 三路影像公司 鉴定患卵巢癌的可能性增加的患者的方法及其组合物
US8034549B2 (en) 2006-02-09 2011-10-11 University Of South Florida Detection of cancer by elevated levels of BCL-2
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US20070207489A1 (en) 2006-02-16 2007-09-06 Pestano Gary A Reagents and methods for cancer prognosis and pathological staging
US20090061454A1 (en) 2006-03-09 2009-03-05 Brody Jerome S Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
US20090098538A1 (en) 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
US7901885B2 (en) 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP3399450A1 (en) 2006-05-18 2018-11-07 Caris MPI, Inc. System and method for determining individualized medical intervention for a disease state
CA2654584A1 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
US8288369B2 (en) 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US7999080B2 (en) 2006-07-13 2011-08-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
US20080014598A1 (en) 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Phospho-specific antibodies to pi3k regulatory subunit and uses thereof
CA2657576C (en) 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
WO2008021483A2 (en) 2006-08-17 2008-02-21 Ordway Research Institute Prognostic and diagnostic method for disease therapy
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
US20080118576A1 (en) 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
US20090280493A1 (en) 2006-09-08 2009-11-12 Siemens Healthcare Diagnostics Inc. Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
RU2009114745A (ru) 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
US7521189B2 (en) 2006-10-12 2009-04-21 Fair Isaac Corporation Devices for generating detectable polymers
JP2010508512A (ja) 2006-10-27 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 転移性結腸直腸癌のアッセイ
AU2007328427A1 (en) 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2087140A2 (en) 2006-11-13 2009-08-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
EP2120909A2 (en) 2006-12-15 2009-11-25 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080226645A1 (en) 2007-01-10 2008-09-18 Wyeth Methods and compositions for assessment and treatment of asthma
US8455188B2 (en) 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
CA2676148A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
US8105796B2 (en) 2007-02-15 2012-01-31 Universita' Degli Studi Di Torino Regulation of expression of PI3Kβ protein in tumors
US9556491B2 (en) 2007-02-26 2017-01-31 John Wayne Cancer Institute Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
MX2009009379A (es) 2007-03-02 2009-09-14 Amgen Inc Metodos y composiciones para tratar enfermedades tumorales.
WO2008112283A2 (en) 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
AU2008226808B2 (en) 2007-03-13 2013-04-18 Amgen Inc. K-ras and B-raf mutations and anti-EGFr antibody therapy
HUE033695T2 (en) 2007-03-13 2017-12-28 Amgen Inc K-RAS mutations and anti-EGFR antibody therapy
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US20080242622A1 (en) 2007-03-19 2008-10-02 Cold Spring Harbor Laboratory Identification of genetic alterations that modulate drug sensitivity in cancer treatments
EP2155897A2 (en) 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
WO2008123867A1 (en) 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
WO2008123866A2 (en) 2007-04-05 2008-10-16 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of ovarian cancer
WO2008143639A2 (en) 2007-04-06 2008-11-27 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of cervical cancer
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008151004A1 (en) 2007-05-31 2008-12-11 Yale University A genetic lesion associated with cancer
RU2010101093A (ru) 2007-06-15 2011-07-20 Юниверсити Оф Саут Флорида (Us) Способы диагностики и лечения рака
CA3056116A1 (en) 2007-06-22 2008-12-31 Randolph Watnick Methods and uses thereof of prosaposin
EP2176665B1 (en) 2007-08-16 2016-03-02 The Royal Institution for the Advancement of Learning / McGill University Tumor cell-derived microvesicles
US8076061B2 (en) 2007-09-07 2011-12-13 Ascentgene, Inc. Method and composition for cancer diagnosis and treatment
CA2639416C (en) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
BRPI0816852A2 (pt) 2007-09-14 2017-06-06 Univ Ohio State Res Found método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.
EP2215258A4 (en) 2007-10-23 2010-12-01 Clinical Genomics Pty Ltd METHOD FOR DIAGNOSING NEOPLASMS
WO2009061297A1 (en) 2007-11-06 2009-05-14 Source Precision Medicine, Inc. Gene expression profiling for identification of cancer
CA2706881A1 (en) 2007-11-30 2009-06-11 Brian Z. Ring Tle3 as a marker for chemotherapy
US20090203015A1 (en) 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
WO2009103790A2 (en) 2008-02-21 2009-08-27 Universite Libre De Bruxelles Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
ES2600165T3 (es) 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
BRPI0906099A2 (pt) 2008-03-06 2015-07-21 Genentech Inc "método de tratamento do câncer em um indivíduo"
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2009124251A1 (en) 2008-04-03 2009-10-08 Sloan-Kettering Institute For Cancer Research Gene signatures for the prognosis of cancer
WO2009126160A1 (en) 2008-04-10 2009-10-15 University Of Florida Research Foundation Compositions and methods for the treatment of prostate carcinoma
US20090269773A1 (en) 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2568053B1 (en) 2008-05-12 2014-04-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US20100069298A1 (en) 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
EP2347009A4 (en) 2008-10-14 2012-05-30 Caris Mpi Inc GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE
CA2779843A1 (en) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics

Also Published As

Publication number Publication date
IL282783B1 (en) 2023-05-01
CO6141496A2 (es) 2010-03-19
IL243717A0 (en) 2016-04-21
AU2007253740A1 (en) 2007-11-29
IL243717A (en) 2017-04-30
US20140113837A1 (en) 2014-04-24
IL243718A (en) 2017-03-30
JP2020005641A (ja) 2020-01-16
WO2007137187A2 (en) 2007-11-29
IL266164B (en) 2021-05-31
CN103424541A (zh) 2013-12-04
IL195266A (en) 2016-02-29
JP2022050488A (ja) 2022-03-30
EP2032980A2 (en) 2009-03-11
US20140038846A1 (en) 2014-02-06
US20140121121A1 (en) 2014-05-01
MX2008014608A (es) 2009-03-31
EP2032980A4 (en) 2012-01-04
IL243719A0 (en) 2016-04-21
CN101449162B (zh) 2013-07-31
US20140371111A1 (en) 2014-12-18
WO2007137187A3 (en) 2008-03-13
US8831890B2 (en) 2014-09-09
US8700335B2 (en) 2014-04-15
RU2008146868A (ru) 2010-06-27
JP2015200678A (ja) 2015-11-12
IL282783B2 (en) 2023-09-01
CN103424541B (zh) 2018-01-30
EP3399450A1 (en) 2018-11-07
BRPI0711011A2 (pt) 2011-08-23
IL251666A0 (en) 2017-06-29
IL243719A (en) 2017-03-30
CN101449162A (zh) 2009-06-03
JP6568551B2 (ja) 2019-08-28
IL195266A0 (en) 2009-08-03
JP2023139147A (ja) 2023-10-03
IL251666B (en) 2019-05-30
US20140149138A1 (en) 2014-05-29
JP2017167150A (ja) 2017-09-21
CA2651995A1 (en) 2007-11-29
KR101356305B1 (ko) 2014-01-28
US20140370582A1 (en) 2014-12-18
US9383365B2 (en) 2016-07-05
JP2009537154A (ja) 2009-10-29
IL301804A (en) 2023-05-01
JP6129251B2 (ja) 2017-05-17
IL282783A (en) 2021-06-30
CA2651995C (en) 2017-04-25
US8914239B2 (en) 2014-12-16
IL243718A0 (en) 2016-04-21
KR20090013198A (ko) 2009-02-04
US20080014146A1 (en) 2008-01-17
US9372193B2 (en) 2016-06-21
JP2013127477A (ja) 2013-06-27
US8880350B2 (en) 2014-11-04
IL266164A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
IL282783A (en) A system and method for determining a personalized medical intervention for a disease stage
IL182332A0 (en) System and method for assessing a patient condition
PL2007434T3 (pl) Sposób i układ do określania czy lek będzie skuteczny u pacjenta z chorobą
EP2043522A4 (en) SYSTEM AND METHOD FOR NON-INVASIVE MEDICAL SENSOR
EP2016390A4 (en) METHOD AND SYSTEM FOR THE QUANTITATIVE HEMOGLOBIN ASSIGNMENT
EP2091410A4 (en) METHOD FOR MANAGING PATIENT INFORMATION
ZA200904308B (en) System and method for managing reduced pressure at a tissue site
IL241919A0 (en) System and method for catheter implantation
EP2080169A4 (en) SYSTEM AND METHOD FOR SEGMENTING A REGION IN A MEDICAL IMAGE
EP2073690A4 (en) SYSTEM AND METHOD FOR PROVIDING HEALTH RATING FOR A PATIENT
EP2069901A4 (en) METHOD AND SYSTEM FOR SELECTION
PL2035989T3 (pl) System i sposób gromadzenia informacji o pacjencie, na podstawie których można wyznaczyć przebieg leczenia cukrzycy
GB0914354D0 (en) Methods and systems for providing clinical documentation for a patient lifetime in a single interface
EP2063782A4 (en) SYSTEM, STORAGE MEDIUM FOR A COMPUTER PROGRAM AND METHOD FOR DISPLAYING MEDICAL IMAGES
GB2436940B (en) System and method for monitoring pre-eclamptic patients
EP1984874A4 (en) SYSTEM AND METHOD FOR MANAGING MANUFACTURING INFORMATION
GB0719556D0 (en) A method and system for data compression
FR2929733B1 (fr) Systeme et procede de securisation d'un ordinateur comportant un micronoyau
TWI318684B (en) Method for imaging a sample and system thereof
GB2447547B (en) Method and system for patient evaluation
HK1127904A (en) System and method for determining individualized medical intervention for a disease state
GB0603912D0 (en) System and method for a picture casket
FI20070866A0 (fi) Järjestelmä ja menetelmä lääketieteellisten tilojen diagnosoimiseksi
ZA200807165B (en) Medical record management system
GB0619694D0 (en) A patient information system